Welcome to our dedicated page for Esperion Therape news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therape stock.
Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a commercial-stage biopharmaceutical company focused on cardiometabolic and rare/orphan disease therapies, with an emphasis on oral, once-daily, non-statin treatments for patients with elevated LDL-C who are at risk for cardiovascular disease. This news page aggregates company announcements, clinical updates, partnership developments, and financial disclosures related to Esperion and its products.
Investors and healthcare-focused readers can use this feed to follow Esperion’s progress with NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), including regulatory milestones, commercialization updates, and guideline-related developments. Recent company communications highlight inclusion of bempedoic acid in major cardiovascular guidelines, presentations of new analyses from the CLEAR Outcomes trial, and expansion of access through partners in Europe, Japan, Canada and other regions.
News items also cover Esperion’s pipeline activities, such as the nomination of ESP-2001, a highly specific allosteric ATP-citrate lyase inhibitor for primary sclerosing cholangitis, and broader ACLY-focused research efforts. Financial and corporate updates, including quarterly results, capital raises via public offerings, and executive appointments, are reported through press releases and Form 8-K filings and are reflected in this news stream.
By reviewing the ESPR news feed, readers can see how Esperion describes its Vision 2040 strategy, commercial execution in the U.S. statin-intolerant market, international launches with partners, and ongoing safety and indication communications for NEXLETOL and NEXLIZET. This page offers a centralized view of the company’s publicly released information over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Esperion (NASDAQ: ESPR) announced that CEO Sheldon Koenig will participate in a fireside chat at the Bank of America Securities 2023 Health Care Conference on May 11, 2023, at 11:40 AM PDT. Interested parties can register for the live webcast through a provided link.
A live audio broadcast will be available on the investor section of Esperion's website, with a replay set to be accessible about two hours post-event and archived for roughly 90 days.
Esperion is focused on developing medicines for patients with cardiovascular diseases, addressing the urgent need for effective treatments to lower LDL-cholesterol levels.
Esperion (NASDAQ: ESPR) announced it will report its first quarter 2023 financial results on May 9, 2023, before the U.S. markets open. Following this, management will host a webcast at 8:00 a.m. ET to discuss the financial results and business progress. The event will be accessible through the investor section of the Esperion website, with a replay available approximately two hours later. Esperion is focused on developing innovative medicines for patients with cardiovascular and cardiometabolic diseases, particularly aiming to manage high cholesterol levels effectively.
Esperion (NASDAQ: ESPR) has announced a performance-based agreement with Currax Pharmaceuticals, allowing Currax’s 72 sales representatives to co-promote its cholesterol-lowering products, NEXLETOL® and NEXLIZET®. This partnership significantly increases the sales force for these products, reflecting Esperion’s commitment to sustained growth. The agreement aims to leverage the positive momentum from the CLEAR Outcomes trial, involving nearly 14,000 patients, which evaluated the cardiovascular benefits of NEXLETOL. Both medications are indicated for patients requiring additional LDL-C reduction. Important safety information includes warnings about hyperuricemia and tendon rupture. The collaboration lasts through the end of 2023, focusing on elevating awareness and utilization of these treatments.